Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.120 +0.050 (+1.23%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Recursion Pharmaceuticals Shares Are Up Today: what's Going On? ↗

April 11, 2025

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Friday after the U.S. Food and Drug Administration announced a significant policy change that could reshape the drug...

Via Benzinga

Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday ↗

April 11, 2025

Via Benzinga

Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket ↗

April 11, 2025

Via Benzinga

Why Recursion Pharmaceuticals Stock Is Sinking Today ↗

March 10, 2025

Via The Motley Fool

Nvidia-Backed Recursion Pharma Soars After-Hours As FDA Eyes AI Over Animal Testing For Drugs: Retail Traders Elated ↗

April 10, 2025

Recursion is a clinical-stage biotech firm using AI, machine learning, and automation to accelerate drug discovery.

Via Stocktwits

Topics Animal Testing Artificial Intelligence

Wondering what's happening in today's after-hours session? ↗

April 10, 2025

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements ↗

April 10, 2025

Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing...

Via Benzinga

Topics Animal Testing

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 10, 2025

Via Benzinga

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

April 09, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

April 08, 2025

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors

From Recursion Pharmaceuticals

Via GlobeNewswire

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March ↗

April 03, 2025

Via The Motley Fool

Topics Bankruptcy Economy World Trade

Recursion to Participate in Upcoming Investor Conference

April 01, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today ↗

March 31, 2025

Via The Motley Fool

Topics Government World Trade

Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks? ↗

March 30, 2025

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks ↗

March 30, 2025

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

March 18, 2025

Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy.

From Recursion Pharmaceuticals

Via GlobeNewswire

Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock ↗

March 10, 2025

Fiserv recently completed its acquisition of Payfare Inc. On "Mad Money Lightning Round," Jim Cramer called it "one of the greatest fintechs."

Via Benzinga

Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy? ↗

March 08, 2025

Via The Motley Fool

Topics Artificial Intelligence

Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip ↗

March 08, 2025

Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX.

Via Benzinga

4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today ↗

March 07, 2025

Via The Motley Fool

This Biotech Stock Could Be the Best Investment of the Decade ↗

March 07, 2025

The term "game-changing" is overused for too many up-and-coming companies, but in this case, the description fits.

Via The Motley Fool

Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip? ↗

March 06, 2025

Via The Motley Fool

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says ↗

March 03, 2025

Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham.

Via Benzinga

Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip ↗

March 02, 2025

Leerink cited concerns over high cash burn and execution risks in deal-making and clinical development over the next year.

Via Stocktwits

Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday ↗

March 01, 2025

Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS.

Via Benzinga

Topics Artificial Intelligence

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

February 28, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Earnings Scheduled For February 28, 2025 ↗

February 28, 2025

Via Benzinga

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

February 24, 2025

Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMT

From Recursion Pharmaceuticals

Via GlobeNewswire

Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?

February 21, 2025

Recursion Pharmaceuticals' stock has soared due to Nvidia's continued investment, positioning the company as a leader in AI-driven drug discovery.

Via MarketBeat

Topics Artificial Intelligence Regulatory Compliance

SoundHound and Serve Robotics Are Dropping Like a Rock -- Why Nvidia Was the Catalyst ↗

February 20, 2025

Nvidia sold their stake in some high-flying stocks recently.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.